CDKL5 and craniodiaphyseal dysplasia: A hit-to-lead campaign would be one approach to improve the pharmacokinetic and brain penetrance of improved analogs of CAF-382 (B1), furnishing others that may be better suited to study the role of CDKL5 in CDD in vivo.